Search Results

Business

Ablexis Announces License Agreement with Adimab

Ablexis, LLC today announced a license agreement with Adimab, LLC (“Adimab”).

February 9, 2023

·

2 min read

Business

Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities

Ablexis, LLC and AlivaMab Discovery Services, LLC announced an expansion of platforms and capabilities in antibody drug discovery and engineering.

November 15, 2022

·

4 min read

Biotech Beach

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development

Ablexis, LLC and AlivaMab Discovery Services, LLC announced a multi-target licensing agreement between Ablexis and Almirall, S.A., a global biopharmaceutical company focused on skin health, and a research partnership between ADS and Almirall.

January 31, 2022

·

5 min read

Business

Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A.

Ablexis grants rights to use the AlivaMab ® Mouse platform for research, development and commercialization of antibodies

May 4, 2021

·

2 min read

Biotech Beach

Ablexis Announces Further Expansion of Its Intellectual Property on AlivaMab® Mouse and Immunoglobulin Locus Engineering

Ablexis, LLC, a biopharmaceutical company focused on licensing its transgenic mouse platforms for antibody drug discovery, today announced further expansion of its intellectual property portfolio directed to its AlivaMab Mouse platform

October 15, 2020

·

2 min read

Business

Ablexis Announces Multi-Target Licensing Agreement with Zai Lab (US)

Ablexis grants rights to use the AlivaMab™ Mouse platform for research, development and potential commercialization of antibodies

June 3, 2019

·

1 min read

Business

Ablexis Announces Licensing Agreement with Corvidia Therapeutics

Ablexis grants rights to Corvidia to use the AlivaMab Mouse™ platform for research, development and potential commercialization of antibodies

January 3, 2019

·

1 min read

Business

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies

Ablexis, LLC , AlivaMab Discovery Services, LLC (“ADS”) and Berkeley Lights, Inc. today announced the rapid generation and recovery of sequences encoding a rich panel of human antibodies against the S1 spike protein of the S

April 22, 2020

·

4 min read

Business

Ablexis Announces Licensing Agreement with Voyager Therapeutics

Ablexis grants rights to Voyager to use the AlivaMab Mouse platform for research, development and potential commercialization of antibodies

October 23, 2018

·

1 min read

Policy

Ablexis Announces Licensing Agreement with Allogene Therapeutics

Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse platform

December 6, 2018

·

1 min read